Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Summary
Novo Nordisk's type-2 diabetes GLP-1 pill is entering Phase 3 trials with potential launch by 2020.
This oral version will likely extend and take a large portion of the injectable GLP-1 market.
It may also get valuable penetration into some significant new markets.
I assess the possibility that Novo's GLP-1 pill sales exceed $10B by 2025.
http://seekingalpha.com/article/371...uld-be-a-10minus-20-billion-super-blockbuster
Victoza in a pill...🙂
Novo Nordisk's type-2 diabetes GLP-1 pill is entering Phase 3 trials with potential launch by 2020.
This oral version will likely extend and take a large portion of the injectable GLP-1 market.
It may also get valuable penetration into some significant new markets.
I assess the possibility that Novo's GLP-1 pill sales exceed $10B by 2025.
http://seekingalpha.com/article/371...uld-be-a-10minus-20-billion-super-blockbuster
Victoza in a pill...🙂